Brooks Laboratories Ltd. IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 3,150,000 (50%) | — | ₹3,150 Cr |
| NII (HNI) | — | 945,000 (15%) | — | ₹945 Cr |
| Retail | — | 2,205,000 (35%) | — | ₹2,205 Cr |
| Σ Total | — | 6,300,000 (100%) | — | ₹63,000 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 60 | ₹6,000 |
| Retail (Max) | 13 | 780 | ₹78,000 |
| S-HNI (Min) | 14 | 840 | ₹84,000 |
| B-HNI (Min) | 67 | 4,020 | ₹402,000 |
Financial Statements Amount in Lakhs
| Metric | 31-Mar-11 | 31-Mar-10 | 31-Mar-09 |
|---|---|---|---|
| Revenue | 5,320 | 4,545 | 4,383 |
| Profit After Tax | 689 | 520 | 296 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- 1 To set up our new manufacturing unit at JB SEZ Pvt Ltd, Panoli, Gujarat for manufacturing of various pharmaceuticals formulations. –
- 2 To meet Long Term Working Capital requirement –
- 3 To meet General Corporate Purpose: and –
- 4 To meet Issue Expenses and Listing of Shares on Stock Exchanges –
Company Overview
Incorporated in 2002, Brooks Laboratories Ltd is in the business of Pharmaceutical Contract Research & Manufacturing. Company manufactures wide range of products catering to critical care segment in Parental Section like Beta Lactam, Cephalosporin & General Dry powder Injectables, Ampoules and Liquid vials, Dry Syrups and Tablets etc.
Brooks Labs has manufacturing unit at Baddi, Himachal Pradesh. Company has a world class team to develop new molecules in injectables and clavulanic acid based products supported by sophisticated infrastructure for Research & Development. Brooks Labs is WHO-GMP and ISO 9000-2008 certified company.
The Indian pharmaceuticals industry is significantly developed in terms of infrastructure, technology and product range in recent years. The country now ranks among the top four worldwide accounting for 8% to 10% of world’s production by volume and 1.5% to 2% by value.